CA2057913C - N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present - Google Patents

N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present

Info

Publication number
CA2057913C
CA2057913C CA002057913A CA2057913A CA2057913C CA 2057913 C CA2057913 C CA 2057913C CA 002057913 A CA002057913 A CA 002057913A CA 2057913 A CA2057913 A CA 2057913A CA 2057913 C CA2057913 C CA 2057913C
Authority
CA
Canada
Prior art keywords
alkyl
group
phenyl
formula
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002057913A
Other languages
English (en)
French (fr)
Other versions
CA2057913A1 (en
Inventor
Claude Bernhart
Jean-Claude Breliere
Jacques Clement
Dino Nisato
Pierre Perreaut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26227935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2057913(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9003563A external-priority patent/FR2659967B1/fr
Priority claimed from FR9010144A external-priority patent/FR2665702B1/fr
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CA2057913A1 publication Critical patent/CA2057913A1/en
Application granted granted Critical
Publication of CA2057913C publication Critical patent/CA2057913C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Paints Or Removers (AREA)
  • Organic Insulating Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002057913A 1990-03-20 1991-03-20 N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present Expired - Lifetime CA2057913C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9003563 1990-03-20
FR9003563A FR2659967B1 (fr) 1990-03-20 1990-03-20 Derives d'imidazolinone n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
FR9010144A FR2665702B1 (fr) 1990-08-08 1990-08-08 Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
FR9010144 1990-08-08

Publications (2)

Publication Number Publication Date
CA2057913A1 CA2057913A1 (en) 1991-09-21
CA2057913C true CA2057913C (en) 1997-07-08

Family

ID=26227935

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002057913A Expired - Lifetime CA2057913C (en) 1990-03-20 1991-03-20 N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present

Country Status (30)

Country Link
EP (1) EP0454511B1 (enrdf_load_html_response)
JP (2) JP2868313B2 (enrdf_load_html_response)
KR (1) KR0175310B1 (enrdf_load_html_response)
AT (1) ATE167475T1 (enrdf_load_html_response)
AU (1) AU641005B2 (enrdf_load_html_response)
CA (1) CA2057913C (enrdf_load_html_response)
CZ (2) CZ287064B6 (enrdf_load_html_response)
DE (2) DE19975029I2 (enrdf_load_html_response)
DK (1) DK0454511T3 (enrdf_load_html_response)
ES (1) ES2119764T3 (enrdf_load_html_response)
FI (1) FI103407B1 (enrdf_load_html_response)
HK (1) HK1008918A1 (enrdf_load_html_response)
HU (3) HUT67648A (enrdf_load_html_response)
IE (1) IE910913A1 (enrdf_load_html_response)
IL (3) IL110820A (enrdf_load_html_response)
LU (2) LU90279I2 (enrdf_load_html_response)
LV (1) LV10439B (enrdf_load_html_response)
MX (1) MX9203586A (enrdf_load_html_response)
MY (1) MY115638A (enrdf_load_html_response)
NL (2) NL980039I2 (enrdf_load_html_response)
NO (3) NO301977B1 (enrdf_load_html_response)
NZ (1) NZ237476A (enrdf_load_html_response)
PL (3) PL166581B1 (enrdf_load_html_response)
PT (1) PT97078B (enrdf_load_html_response)
RU (1) RU2099331C1 (enrdf_load_html_response)
SG (1) SG49053A1 (enrdf_load_html_response)
SK (2) SK283197B6 (enrdf_load_html_response)
TW (1) TW201738B (enrdf_load_html_response)
UA (1) UA42669A (enrdf_load_html_response)
WO (1) WO1991014679A1 (enrdf_load_html_response)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19675036I2 (de) * 1990-02-19 2004-10-21 Novartis Ag Acylverbindungen.
CA2053148A1 (en) * 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
AU656551B2 (en) * 1990-12-14 1995-02-09 Smithkline Beecham Corporation Angiotensin II receptor blocking compositions
FR2673427B1 (fr) * 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
AU1625192A (en) * 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
EP0601039A1 (en) * 1991-08-19 1994-06-15 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
EP0599999A1 (en) * 1991-08-19 1994-06-08 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
US5182288A (en) * 1991-11-13 1993-01-26 Ortho Pharmaceutical Corporation Substituted n-biphenylyl lactams
FR2685328B1 (fr) * 1991-12-20 1995-12-01 Rhone Poulenc Agrochimie Derives de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
ZA931063B (en) * 1992-02-17 1993-09-23 Ciba Geigy Treatment of glaucoma.
WO1993017681A1 (en) * 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
FR2688781B1 (fr) * 1992-03-23 1994-07-01 Sanofi Elf Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
FR2689887B1 (fr) * 1992-04-13 1995-06-23 Sanofi Elf Procede de preparation d'un derive de biphenyle.
EP0577025A3 (de) * 1992-07-01 1998-02-04 Hoechst Aktiengesellschaft Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
EP0603712B1 (en) * 1992-12-22 2001-08-16 Takeda Chemical Industries, Ltd. Heterocyclic compounds having angiotensin II antagonistic activity and use thereof
FR2711367B1 (fr) * 1993-10-19 1995-12-01 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
US5338740A (en) * 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
US5411641A (en) * 1993-11-22 1995-05-02 E. I. Du Pont De Nemours And Company Electrochemical conversion of anhydrous hydrogen halide to halogen gas using a cation-transporting membrane
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
SE9501881D0 (sv) * 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII-receptor antagonists
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
PT853477E (pt) * 1995-10-06 2003-01-31 Novartis Ag Antagonistas de receptores at1 para prevencao e tratamento de insuficiencia renal pos-isquemica e para proteccao de rim isquemico
CA2196263C (en) * 1996-02-09 2004-10-26 Barry Jackson Process for the preparation of 4-oxoimidazolinium salts
US6174910B1 (en) 1996-02-29 2001-01-16 Novartis Ag AT1 receptor antagonist for the stimulation of apoptosis
TR199801807T2 (xx) * 1996-03-14 1998-12-21 Warner-Lambert Company Farmas�tik maddeler olarak yeni ikame edilmi� siklik amino asitler.
HU218681B (hu) 1997-07-25 2000-10-30 Sanofi-Synthelabo Eljárás 1,3-diaza-spiro(4,4)non-1-én-4-on-származékok előállitására és 1-ciano-1-(acil-amino)-ciklopentán intermedierek
US6162922A (en) * 1998-01-30 2000-12-19 Bristol-Myers Squibb Co. Method for preparing N-substituted heterocyclic derivatives using a phase-transfer catalyst
CA2325472A1 (en) * 1998-03-25 1999-09-30 Graham S. Poindexter Imidazolone anorectic agents: iii. heteroaryl derivatives
KR19990081093A (ko) * 1998-04-25 1999-11-15 조생현 피리미디논 화합물, 이를 함유하는 약제학적 조성물 및 이의제조방법
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
FR2780403B3 (fr) 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
UA56338C2 (uk) * 1998-07-29 2003-05-15 Іхара Кемікал Індастрі Ко., Лтд. Похідні ди- або трифторметансульфоніланіліду, спосіб їх одержання і гербіциди, що містять вказані похідні як активні інгредієнти
EP1588706B1 (en) 1998-12-23 2011-09-14 Novartis AG Valsartan tablet
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
RU2263675C2 (ru) * 2001-09-21 2005-11-10 Бориюнг Фармасьютикал Ко., Лтд. Способ получения пиримидинонового соединения и его фармацевтически приемлемых солей
FR2831446B1 (fr) * 2001-10-26 2004-03-05 Sanofi Synthelabo Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
EP1977741A3 (en) 2004-03-17 2009-10-14 Novartis AG Use of renin inhibitors in therapy
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
WO2005122699A2 (en) * 2004-06-16 2005-12-29 Matrix Laboratories Ltd An improved process for the preparation of n-substituted hetero cyclic derivatives
SI21849A (sl) 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
TWI346108B (en) * 2004-08-23 2011-08-01 Bristol Myers Squibb Co A method for preparing irbesartan and intermediates thereof
ATE551052T1 (de) 2004-10-08 2012-04-15 Novartis Ag Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
GB2419592A (en) 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
RU2007115900A (ru) 2004-10-27 2008-11-10 Дайити Санкио Компани, Лимитед (Jp) Производные бензола, имеющие 2 или более заместителей
FR2886642B1 (fr) * 2005-06-06 2008-05-30 Sanofi Aventis Sa Sels alcalino-terreux d'irbesartan et leur preparation
EP1749828A1 (en) 2005-08-04 2007-02-07 Farmaprojects S.L. Process for preparing an angiotensin II receptor antagonist
WO2007049293A1 (en) 2005-10-28 2007-05-03 Alembic Limited An improved process for preparation of irbesartan
ES2340701T3 (es) 2006-01-09 2010-06-08 Krka, D.D., Novo Mesto Composicion farmaceutica solida que comprende irbesartan.
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP1918288A1 (en) 2006-11-02 2008-05-07 Cadila Pharmaceuticals Limited A novel and improved process for the preparation of Irbesartan, an angiotensin-II receptor antagonist for the treatment of hypertension
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
CN101772513B (zh) 2007-06-04 2013-11-13 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP2011500633A (ja) 2007-10-16 2011-01-06 ノバルティス アーゲー ４−フェニル−５−オキソ−イミダゾール誘導体、その医薬組成物および使用
DE602007007968D1 (de) 2007-11-28 2010-09-02 Lesvi Laboratorios Sl Pharmazeutische Formulierungen mit Irbesartan
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009149734A1 (en) * 2008-06-13 2009-12-17 Ratiopharm Gmbh Process for the preparation of irbesartan and intermediate products
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2194050A1 (en) 2008-12-08 2010-06-09 KRKA, tovarna zdravil, d.d., Novo mesto A new process for the preparation of irbesartan
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
HUP0900788A2 (en) 2009-12-16 2011-11-28 Sanofi Aventis Process for producing 4-bromomethyl-biphenyl derivatives
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
AP2014007766A0 (en) 2011-12-15 2014-07-31 Takeda Pharmaceuticals Usa Inc Combination os azilsartan and chlorthlidone for treating hypertension black patients
PL223830B1 (pl) 2012-04-03 2016-11-30 Univ Jagiellonski Pochodne aromatycznych imidazolidynonów i ich zastosowanie
HK1220696A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 鸟苷酸环化酶激动剂及其用途
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治療胃腸道病症的組成物
PT3004138T (pt) 2013-06-05 2024-06-18 Bausch Health Ireland Ltd Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos
WO2015012205A1 (ja) 2013-07-23 2015-01-29 第一三共株式会社 高血圧症の予防又は治療のための医薬
CA3015964C (en) 2016-03-24 2021-08-03 Daiichi Sankyo Company, Limited Medicine for treating renal disease
LT3648761T (lt) 2017-07-07 2024-06-10 Boehringer Ingelheim Vetmedica Gmbh Telmisartanas, skirtas kačių hipertenzijos profilaktikai arba gydymui
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2024240633A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
WO2025125409A1 (en) 2023-12-15 2025-06-19 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3340595A1 (de) * 1983-11-10 1985-05-23 Hoechst Ag, 6230 Frankfurt Imidazolinone, verfahren zu ihrer herstellung und ihre verwendung im pflanzenschutz
DE3545597A1 (de) * 1985-12-21 1987-07-02 Celamerck Gmbh & Co Kg Neue herbizid wirksame imidazolinone
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
EP0303863A3 (en) * 1987-08-17 1991-10-23 American Cyanamid Company Benzenesulfonyl carboxamide compounds, intermediate compounds and methods of preparation thereof and use of said compounds and intermediate compounds as herbicidal agents
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
EP0407342A3 (en) * 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
EP0412594B1 (en) * 1989-07-28 1996-01-03 Merck & Co. Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
DE69013607T2 (de) * 1989-08-02 1995-03-02 Takeda Chemical Industries Ltd Pyrazol-Derivate, Verfahren zu deren Herstellung und Anwendung.
US5100897A (en) * 1989-08-28 1992-03-31 Merck & Co., Inc. Substituted pyrimidinones as angiotensin ii antagonists
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds

Also Published As

Publication number Publication date
LV10439A (lv) 1995-02-20
IL110820A0 (en) 1994-11-11
NO914528L (no) 1992-01-17
IL110820A (en) 1995-11-27
MY115638A (en) 2003-08-30
CZ287064B6 (cs) 2000-08-16
EP0454511B1 (fr) 1998-06-17
SK283197B6 (sk) 2003-03-04
NO1999025I1 (no) 1999-12-09
UA42669A (uk) 2001-11-15
FI915458A0 (fi) 1991-11-19
IL97612A (en) 1995-08-31
DE19975029I2 (de) 2002-05-08
IE910913A1 (en) 1991-09-25
FI103407B (fi) 1999-06-30
HK1008918A1 (en) 1999-05-21
KR920702349A (ko) 1992-09-03
LV10439B (en) 1995-08-20
NO914528D0 (no) 1991-11-19
TW201738B (enrdf_load_html_response) 1993-03-11
WO1991014679A1 (fr) 1991-10-03
KR0175310B1 (ko) 1999-02-18
EP0454511A1 (fr) 1991-10-30
ES2119764T3 (es) 1998-10-16
HU9302497D0 (en) 1993-11-29
JP2868313B2 (ja) 1999-03-10
FI103407B1 (fi) 1999-06-30
ATE167475T1 (de) 1998-07-15
HU221188B1 (en) 2002-08-28
MX9203586A (es) 1992-07-01
RU2099331C1 (ru) 1997-12-20
AU7561091A (en) 1991-10-21
LU90371I2 (fr) 1999-05-12
PL165945B1 (pl) 1995-03-31
PL293015A1 (enrdf_load_html_response) 1993-02-08
NL990006I1 (nl) 1999-05-03
NL990006I2 (nl) 1999-10-01
LU90279I2 (fr) 1998-10-21
PL166581B1 (pl) 1995-06-30
DK0454511T3 (da) 1999-04-06
NZ237476A (en) 1994-01-26
SG49053A1 (en) 1998-05-18
CZ287225B6 (cs) 2000-10-11
AU641005B2 (en) 1993-09-09
HU913603D0 (en) 1992-07-28
CS74591A3 (en) 1991-11-12
DE69129606D1 (de) 1998-07-23
JPH04506222A (ja) 1992-10-29
NL980039I1 (nl) 1999-02-01
PT97078A (pt) 1991-11-29
IL97612A0 (en) 1992-06-21
NO1998021I1 (no) 1998-10-05
HUT67648A (en) 1995-04-28
NO301977B1 (no) 1998-01-05
SK280096B6 (sk) 1999-08-06
HU223141B1 (hu) 2004-03-29
PT97078B (pt) 1997-07-31
NL980039I2 (nl) 1999-09-01
DE69129606T2 (de) 1998-12-17
JPH10279566A (ja) 1998-10-20
CA2057913A1 (en) 1991-09-21
PL166403B1 (pl) 1995-05-31
HUT61284A (en) 1992-12-28

Similar Documents

Publication Publication Date Title
CA2057913C (en) N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5352788A (en) N-substituted heterocyclic derivatives
JP4211394B2 (ja) プロパン−１，３−ジオン誘導体
US5268375A (en) Dinitrogen heterocyclic derivatives N-substituted by a biphenylmethyl group, and the pharmaceutical compositions in which they are present
HK1008918B (en) N-substituted heterocycle derivatives, their preparation, compositions containing them
JPH07215947A (ja) １−ベンゼンスルホニル−１，３−ジヒドロ−２ｈ−ベンズイミダゾール−２−オン誘導体
IL103116A (en) History of N-transformed heterocyclics, pharmaceutical preparations containing certain compounds and their preparation
JPH0873439A (ja) １−ベンジル−１，３−ジヒドロ−２ｈ−ベンズイミダゾール−２−オン誘導体、これらの調製およびこれらを含有する薬学的組成物
US5434167A (en) Imidazolines N-substituted by a biphenylmethyl group, their medical use and the pharmaceutical compositions therefor
LT3376B (en) N-substituted heterocyclic derivatives, process fof their preparation, intermediates, process for their preparation and pharmaceutical composition
FR2665702A1 (fr) Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry